BMJ Open Respiratory Research · 2019 · 14 citations · 13 references
MedicineClinical SciencesRespiratory TherapyPulmonary Function TestingPulmonologyVentilationAirway Clearance TechniquesAirway ObstructionBreathing SupportCystic FibrosisForced Expiratory VolumeMechanical VentilationAirway Clearance In BronchiectasisForced Expiratory Volume AssessmentForced Expiratory Volume DeclineOxygen RequirementsPatient Effort AssessmentPrimary Outcome AnalysisPulmonary ExacerbationsSputum Clearance
Introduction Non-invasive ventilation (NIV) is used in cystic fibrosis (CF) to support airway clearance techniques (ACTs) by augmenting tidal volumes and reducing patient effort. However, the evidence base for this is limited. We hypothesised that NIV, in addition to usual ACT, would increase sputum clearance. In addition, we investigated ease of sputum clearance (EoC), work of breathing (WoB) and NIV tolerability. Methods Adults with CF (16+ years) at the end of hospitalisation for a pulmonary exacerbation were randomised to a cross-over trial of NIV-supported ACT or ACT alone in two consecutive days. No other changes to standard care were made. The primary outcome was the total 24-hour expectorated sputum wet weight after the intervention. Spirometry was completed pre-treatment and post-treatment. Oxygen saturations were measured pre-treatment, during treatment and post-treatment. EoC and WoB were assessed using Visual Analogue Scale. Results 14 subjects completed the study (7 male, mean age 35 [SD 17] years, mean forced expiratory volume in 1 s [FEV 1 ] 49 [20] % predicted). The difference between treatment regimens was −0.98 g sputum (95% CI −11.5 to 9.6, p=0.84) over 24 hours. During treatment oxygen saturations were significantly higher with NIV-supported ACT (mean difference 2.0, 95% CI 0.9 to 2.6, p=0.0004). No other significant differences were found in post-treatment FEV 1 , EoC, WoB, oxygen saturations or subject preference. Conclusions There was no difference in treatment effect between NIV-supported ACT and ACT alone, although the study was underpowered. Oxygen saturations were significantly higher during NIV-supported ACT, but with no effect on post-treatment saturations. NIV was well tolerated. Trial registration number NCT01885650 .
13
Martin R. Miller, J. Hankinson, Vito Brusasco et al. · European Respiratory Journal · 2005 · 15.7K citations · Full text